Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?

Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?

OBJECTIVE: To measure the cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with established ischaemic heart disease and average baseline cholesterol levels. DESIGN: Prospective economic evaluation within a double-blind randomised trial (Long-Term Intervention with Pra...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Glasziou, P, Eckermann, S, Mulray, SE, Simes, R, Martin, A, Kirby, A, Hall, J, Caleo, S, White, H, Tonkin, A
Format:	Journal article
Sprache:	English
Veröffentlicht:	2002

Ähnliche Einträge

Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
von: Tonkin, A, et al.
Veröffentlicht: (2006)

Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
von: Colquhoun, D, et al.
Veröffentlicht: (2004)

Pravastatin therapy and the risk of stroke.
von: White, H, et al.
Veröffentlicht: (2000)

Detection of 4a,5-dihydropravastatin as Impurity in the Cholesterol Lowering Drug Pravastatin
von: Wibo B. van Scheppingen, et al.
Veröffentlicht: (2021-08-01)

Monitoring cholesterol levels: measurement error or true change?
von: Glasziou, P, et al.
Veröffentlicht: (2008)

Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long‐term Intervention with Pravastatin in Ischaemic Disease (LIPID) study
von: Dianna Magliano, et al.
Veröffentlicht: (2003-12-01)

Comparison of fat intake in Australian and New Zealand CHD patients: The LIPID (long term intervention with Pravastatin in ischaemic disease) study
von: Nestel, P, et al.
Veröffentlicht: (2002)

Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease.
von: Reid, I, et al.
Veröffentlicht: (2001)

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
von: LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Veröffentlicht: (2002)

Efficacy and safety of cholesterol-lowering treatment - Reply
von: Baigent, C, et al.
Veröffentlicht: (2006)

Efficacy and safety of cholesterol-lowering treatment - Reply
von: Baigent, C, et al.
Veröffentlicht: (2006)

Hypocholesterolemic Effect of Pravastatin is Associated with Increased Content of Antioxidant Vitamin-E in Cholesterol Fractions
von: Vladimír Bláha, et al.
Veröffentlicht: (1998-01-01)

Hyperlipoproteinemia in Nagase analbuminemic rats: effects of pravastatin on plasma (apo)lipoproteins and lecithin:cholesterol acyltransferase activity.
von: A Van Tol, et al.
Veröffentlicht: (1991-11-01)

Effects of single-dose morning and evening administration of pravastatin on antioxidant markers in cholesterol-fed rabbits
von: Kamal S
Veröffentlicht: (2011-05-01)

Lower than average HDL cholesterol efflux capacity in Lithuanian population
von: Sandra Kutkiene, et al.
Veröffentlicht: (2019-10-01)

Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.
von: Tonkin, A, et al.
Veröffentlicht: (2000)

Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators.
von: Marschner, I, et al.
Veröffentlicht: (2001)

Cholesterol induced heart valve inflammation and injury: efficacy of cholesterol lowering treatment
von: Layan A El-Khatib, et al.
Veröffentlicht: (2020-12-01)

Nonpharmacological cholesterol-lowering approach: Managing cholesterol naturally
von: Lubna Mahmood
Veröffentlicht: (2015-01-01)

Pravastatin polarizes the phenotype of macrophages toward M2 and elevates serum cholesterol levels in apolipoprotein E knockout mice
von: Xiaoling Zhang, et al.
Veröffentlicht: (2018-08-01)

Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial
von: Nirupa R. Matthan, et al.
Veröffentlicht: (2010-01-01)

Healthy eating for lower cholesterol /
von: Green, Daniel, et al.
Veröffentlicht: (c200)

Cholesterol level lowering liposomes
von: Pollock, S, et al.
Veröffentlicht: (2012)

Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data.
von: Bell, K, et al.
Veröffentlicht: (2011)

Monitoring adherence to drug treatment by using change in cholesterol concentration: Secondary analysis of trial data
von: Bell, K, et al.
Veröffentlicht: (2011)

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
von: Baigent, C, et al.
Veröffentlicht: (2005)

Sibu olive inhibits artherosclerosis by cholesterol lowering effect in cholesterol fed-rabbit
von: M.H., Nurulhuda, et al.
Veröffentlicht: (2012)

Cholesterol deficiency carriers have lowered serum cholesterol and perform well at an elite cattle show
von: B.L. Basiel, et al.
Veröffentlicht: (2020-08-01)

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group.
von: Wardle, J, et al.
Veröffentlicht: (1996)

CHOLESTEROL LOWERING TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT
von: Collins, R
Veröffentlicht: (1993)

PRODUCING OF BACTERIAL CONCENTRATES WITH HIGH CHOLESTEROL LOWERING ACTIVITY
von: Khamagaeva I.S., et al.
Veröffentlicht: (2016-06-01)

Pravastatin Modulate Niemann-Pick C1-Like 1 and ATP-Binding Cassette G5 and G8 to Influence Intestinal Cholesterol Absorption
von: Atsushi Kawase, et al.
Veröffentlicht: (2015-11-01)

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
von: Kearney, P, et al.
Veröffentlicht: (2008)

Ezetimibe and diabetes mellitus:a new strategy for lowering cholesterol
von: V.A. Serhiyenko, et al.
Veröffentlicht: (2022-09-01)

CHOLESTEROL-LOWERING TRIAL RESULTS IN THEIR EPIDEMIOLOGIC CONTEXT
von: Peto, R, et al.
Veröffentlicht: (1985)

Policosanols lose their lustre as cholesterol-lowering agents
von: Peter J.H. Jones, et al.
Veröffentlicht: (2009-04-01)

Role and classification of cholesterol-lowering functional foods
von: Zhen-Yu Chen, et al.
Veröffentlicht: (2011-04-01)

Cholesterol: until which age 'the lower the better'?
von: Niccolò Marchionni, et al.
Veröffentlicht: (2016-06-01)

Effects of lowering LDL cholesterol on progression of kidney disease.
von: Haynes, R, et al.
Veröffentlicht: (2014)

Cholesterol and total mortality: need for larger trials.
von: Collins, R, et al.
Veröffentlicht: (1992)